Prednisolone/Prednisone is named as an intervention in 2 current clinical trials in our China, UK, USA and India registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Prostate Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803 · Prostate Cancer
|
Phase 3 | Recruiting | AstraZeneca | UK, USA, India, China |
|
Rituximab in the First Episode of Paediatric Nephrotic Syndrome
NCT05850546 · ClinicalTrials.gov ↗ · Steroid-Sensitive Nephrotic Syndrome
|
Phase 3 | Not yet open | Children's Hospital of Fudan University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Children's Hospital of Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, UK, USA and India registers name Prednisolone/Prednisone as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China, 1 with sites in UK, 1 with sites in USA and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1) and Children's Hospital of Fudan University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Prednisolone/Prednisone works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Prednisolone/Prednisone works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Prednisolone/Prednisone (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.